Personal information

Countries

United States

Activities

Collapse all

Employment (3)

University of Illinois Chicago College of Pharmacy: Chicago, IL, US

2022-09-01 to present
Employment
Source: Self-asserted source
Michael Buege

Memorial Sloan Kettering Cancer Center: New York, NY, US

2018-08-20 to present | Clinical Pharmacy Specialist (Clinical coordinators)
Employment
Source: check_circle
Memorial Sloan Kettering Cancer Center

University of Texas MD Anderson Cancer Center: Houston, TX, US

2016-06-20 to 2018-07-16
Employment
Source: Self-asserted source
Michael Buege

Education and qualifications (1)

Drake University: Des Moines, IA, US

2010-08 to 2016-05 | PharmD
Education
Source: Self-asserted source
Michael Buege

Works (11)

Time to progression of disease and outcomes with second-line BTK inhibitors in relapsed/refractory mantle cell lymphoma

Blood Advances
2023-08-22 | Journal article
DOI: 10.1182/bloodadvances.2023009804
Contributors: Diego Villa; Aixiang Jiang; Carlo Visco; Nicola Crosbie; Rory McCulloch; Michael J. Buege; Anita Kumar; David A. Bond; Jonas Paludo; Matthew J. Maurer et al.
Source: check_circle
Crossref

Low incidence of cardiotoxicity in patients with non‐Hodgkin lymphoma receiving EPOCH after prior anthracycline exposure

European Journal of Haematology
2023-07 | Journal article
DOI: 10.1111/ejh.13971
Contributors: Michael J. Buege; Esther Drill; Steven M. Horwitz; Andréa LeVoir; Terry Pak; Tim J. Peterson; Phuong H. Dao; Matthew J. Matasar
Source: check_circle
Crossref

Successful implementation of outpatient R ± DHAX (rituximab, dexamethasone, oxaliplatin, cytarabine) for select patients with lymphoma: a single-center experience

Leukemia & Lymphoma
2022-03-21 | Journal article
DOI: 10.1080/10428194.2021.2002318
Contributors: Terry K. Pak; Brianne N. Dixon; Michael J. Buege; Phuong H. Dao; Megan H. Leary; Joy C. Jarrett; Tara A. Duggan; Philip Caron; Lorenzo Falchi; Paul Hamlin et al.
Source: check_circle
Crossref

Outpatient clinical pharmacy practice in the face of COVID-19 at a cancer center in New York City

Journal of Oncology Pharmacy Practice
2021-03 | Journal article
DOI: 10.1177/1078155220987625
Contributors: Prakirthi Yerram; Jennifer Thackray; Lisa R Modelevsky; Josiah D Land; Samantha N Reiss; Krisoula H Spatz; Andrea C Levoir; Terry K Pak; Phuong H Dao; Michael J Buege et al.
Source: check_circle
Crossref

Management of Mantle Cell Lymphoma in the Era of Novel Oral Agents

Annals of Pharmacotherapy
2020-09 | Journal article
DOI: 10.1177/1060028020909117
Contributors: Michael J. Buege; Anita Kumar; Brianne N. Dixon; Laura A. Tang; Terry Pak; Jennifer Orozco; Tim J. Peterson; Kathryn T. Maples
Source: check_circle
Crossref

Selinexor: A First-in-Class Nuclear Export Inhibitor for Management of Multiply Relapsed Multiple Myeloma

Annals of Pharmacotherapy
2020-06 | Journal article
DOI: 10.1177/1060028019892643
Contributors: Tim J. Peterson; Jennifer Orozco; Michael Buege
Source: check_circle
Crossref

Corrected calcium versus ionized calcium measurements for identifying hypercalcemia in patients with multiple myeloma

Cancer Treatment and Research Communications
2019 | Journal article
DOI: 10.1016/j.ctarc.2019.100159
Contributors: Michael J. Buege; Bryan Do; Hans C. Lee; Donna M. Weber; Sandra B. Horowitz; Lei Feng; Yun Qing; Brandon R. Shank
Source: check_circle
Crossref

Evolving Treatment Strategies for Elderly Leukemia Patients with IDH Mutations

Cancers
2018-06-06 | Journal article
DOI: 10.3390/cancers10060187
Part of ISSN: 2072-6694
Contributors: Michael Buege; Adam DiPippo; Courtney DiNardo
Source: Self-asserted source
Michael Buege via Crossref Metadata Search

Solithromycin: A novel ketolide antibiotic

American Journal of Health-System Pharmacy
2017-04 | Journal article
DOI: 10.2146/ajhp160934
Part of ISSN: 1079-2082
Contributors: Michael J. Buege; Jack E. Brown; Samuel L. Aitken
Source: Self-asserted source
Michael Buege via Crossref Metadata Search

Clinical Trials of Poly(ADP-Ribose) Polymerase Inhibitors for Cancer Therapy: A Review

Reviews on Recent Clinical Trials
2015-10 | Journal article
DOI: 10.2174/1574887110666150729125809
Part of ISSN: 1574-8871
Contributors: Michael Buege; Pramod Mahajan
Source: Self-asserted source
Michael Buege via Crossref Metadata Search

Mitigation of acute kidney injury by cell-cycle inhibitors that suppress both CDK4/6 and OCT2 functions

Proceedings of the National Academy of Sciences
2015-04-06 | Journal article
DOI: 10.1073/pnas.1424313112
Part of ISSN: 0027-8424
Contributors: Navjotsingh Pabla; Alice A. Gibson; Mike Buege; Su Sien Ong; Lie Li; Shuiying Hu; Guoqing Du; Jason A. Sprowl; Aksana Vasilyeva; Laura J. Janke et al.
Source: Self-asserted source
Michael Buege via Crossref Metadata Search

Peer review (5 reviews for 4 publications/grants)

Review activity for BMC cancer (2)
Review activity for Chest. (1)
Review activity for Clinica chimica acta. (1)
Review activity for Translational oncology. (1)
How many people are using ORCID?